Topic:

Manufacturing

Latest Headlines

Latest Headlines

Indian regulator places 5-year ban on Kivi Labs for forgery

India authorities placed a 5-year ban on Kivi Labs for submitting any filings with the Central Drugs Standards Control Organization after determining the company filed fictitious and forged documents for fixed-dosage combinations.

Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot

Flu vaccine maker Protein Sciences may be abandoning its expansion plans in Connecticut, opting instead to build out its New York-based manufacturing site. But it's not for any of the reasons one might expect.

Indonesia's Kalbe Farma recalls anesthetic, cardio drugs for quality control

Kalbe Farma said it has ordered a recall two of its drugs in Indonesia, an anesthetic and cardiovascular treatment, but did not identify the problem other than to say it was a quality control procedure.

Glenmark scours for partners to market 7 molecules in development

Glenmark's chairman and managing director says his company is looking for a series of partners around the world to market 7 molecules for various treatments it has in development, all but one in clinical trials.

Swine flu outbreak in India bumps demand for generic therapies

An outbreak of the H1N1A influenza--once known as "swine flu"--has led to a run on generic drugs relied on for treatment, prompting the government to urge local makers to step up production.

China FDA notes meeting with U.S. counterparts, but no details

China and U.S. drug officials held their first working meeting of the year recently, China's FDA revealed.

Bangladesh's drug industry meets nearly all domestic demand, eyes exports

Bangladesh's pharmaceuticals industry has become a $1.5 billion business producing 97% of the nation's consumption, but it has a long way to go in various segments including exports, according to Shawkat Haider, general manager of Beximco Pharmaceuticals.

Serum Institute of India poses challenge to Merck HPV vaccine

The Serum Institute of India, the world's fifth largest vaccinemaker by volume, is eyeing newer vaccines, including one for the human papillomavirus expected to be launched by late 2018 and sell at a third of the price of Merck & Co.'s blockbuster Gardasil, Bloomberg reported.

AMRI spends $60M to beef up its manufacturing heft

AMRI, on the mend after a rough quarter, is laying out $60 million to expand its manufacturing footprint, agreeing to buy a couple of outposts from service provider Aptuit.

AMRI gets its desert branch back online after a profit-sapping outage

After a weather-related shutdown at a New Mexico facility helped tank its quarterly earnings, AMRI has rectified the issue, bringing its plant back online as it works to get back on the path to growth.